Zhao Xingtao, Li Liao, Zhou Mengting, Liu Meichen, Deng Ying, He Linfeng, Guo Chaocheng, Li Yunxia
School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Key Laboratory of Standardization for Chinese Herbal Medicine, Ministry of Education, Chengdu 611137, China.
Evid Based Complement Alternat Med. 2020 Sep 16;2020:4875764. doi: 10.1155/2020/4875764. eCollection 2020.
Alcohol liver disease (ALD) caused by excessive alcohol consumption is a progressive disease, and alcohol fatty liver disease is the primary stage. Currently, there is no approved drug for its treatment. Abstinence is the best way to heal, but patients' compliance is poor. Unlike other chronic diseases, alcohol fatty liver disease is not caused by nutritional deficiencies; it is caused by the molecular action of ingested alcohol and its metabolites. More and more studies have shown the potential of Pursh (PCP) in the clinical use of alcohol fatty liver treatment. The purpose of this paper is to reveal from the essence of PCP treatment of alcohol liver mechanism mainly by the ethanol dehydrogenase (ADH) and microsomal ethanol oxidation system-dependent cytochrome P4502E1 (CYP2E1) to exert antilipogenesis, antioxidant, anti-inflammatory, antiapoptotic, and autophagy effects, with special emphasis on its mechanisms related to SIRT1/AMPK, KEAP-1/Nrf2, and TLR4/NF-B. Overall, data from the literature shows that PCP appears to be a promising hepatoprotective traditional Chinese medicine (TCM).
过量饮酒引起的酒精性肝病（ALD）是一种进行性疾病，酒精性脂肪肝病是其主要阶段。目前，尚无获批用于治疗该病的药物。戒酒是最佳治疗方法，但患者依从性较差。与其他慢性疾病不同，酒精性脂肪肝病并非由营养缺乏引起，而是由摄入的酒精及其代谢产物的分子作用所致。越来越多的研究显示了虎杖（PCP）在酒精性脂肪肝病临床治疗中的潜力。本文旨在从本质上揭示PCP治疗酒精性肝病的机制，主要是通过乙醇脱氢酶（ADH）和微粒体乙醇氧化系统依赖的细胞色素P4502E1（CYP2E1）发挥抗脂肪生成、抗氧化、抗炎、抗凋亡和自噬作用，特别强调其与SIRT1/AMPK、KEAP-1/Nrf2和TLR4/NF-κB相关的机制。总体而言，文献数据表明PCP似乎是一种有前景的保肝中药（TCM）。
